为胶质母细胞瘤患者提供颅内 CAR-T 细胞。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-05-22 DOI:10.1016/j.trecan.2024.05.002

Philippa Vaughn-Beaucaire, Moon Jung Choi, Olin Liang, Sean E Lawler

{"title":"为胶质母细胞瘤患者提供颅内 CAR-T 细胞。","authors":"Philippa Vaughn-Beaucaire, Moon Jung Choi, Olin Liang, Sean E Lawler","doi":"10.1016/j.trecan.2024.05.002","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising approach for improving outcomes in high-grade glioma. Here, we highlight three recent studies that reported safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM) as well as preliminary evidence of potential responses, supporting further investigations of this approach.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"478-480"},"PeriodicalIF":14.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intracranial CAR-T cell delivery in glioblastoma patients.\",\"authors\":\"Philippa Vaughn-Beaucaire, Moon Jung Choi, Olin Liang, Sean E Lawler\",\"doi\":\"10.1016/j.trecan.2024.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising approach for improving outcomes in high-grade glioma. Here, we highlight three recent studies that reported safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM) as well as preliminary evidence of potential responses, supporting further investigations of this approach.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"478-480\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.05.002\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.05.002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体（CAR）-T 细胞疗法正在成为改善高级别胶质瘤治疗效果的一种有前途的方法。在此，我们重点介绍最近的三项研究，这些研究报告了在胶质母细胞瘤（GBM）患者中进行颅内 CAR-T 细胞给药的安全性和可行性，以及潜在反应的初步证据，支持对这种方法的进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intracranial CAR-T cell delivery in glioblastoma patients.

Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising approach for improving outcomes in high-grade glioma. Here, we highlight three recent studies that reported safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM) as well as preliminary evidence of potential responses, supporting further investigations of this approach.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.